Texas Oncology - Grapevine
Welcome,         Profile    Billing    Logout  
 15 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ma, Cynthia X
ELEGANT, NCT06492616: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Recruiting
3
4220
US
Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
Stemline Therapeutics, Inc.
Breast Cancer
08/29
10/32
ALTERNATE, NCT01953588: Fulvestrant And/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery

Active, not recruiting
3
1473
US
fulvestrant, Faslodex®, anastrozole, Arimidex®
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
08/25
08/25
NCT03007979: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Completed
2
55
US
Palbociclib, Ibrance, Letrozole, Femara, Fulvestrant, Faslodex, Optional research biopsy, Goserelin, Zoladex, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Washington University School of Medicine, Pfizer
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
03/20
03/23
NeoPalAna, NCT01723774: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Active, not recruiting
2
84
US
PD0332991, Anastrozole, Arimidex®, Goserelin, Zoladex®, Decapeptide I, Surgery (standard of care), Tumor biopsy
Washington University School of Medicine, Pfizer
Breast Neoplasms
04/21
08/26
SWIFT RT, NCT06559540: Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer

Recruiting
2
220
US
Hypofractionated radiation, RT, Ultra-hypofractionated breast/chest wall and regional nodal radiation, SWIFT RT
Washington University School of Medicine
Node-positive Breast Cancer
04/34
04/34
NCT02476786: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Recruiting
2
50
US
FACT-B, Goserelin, Goserelin acetate, Zoladex, Anastrozole, Arimidex®, Exemestane, Aromasin®, Fulvestrant, Faslodex®, Tamoxifen, Nolvadex®, Archived tissue collection
Washington University School of Medicine, Genomic Health®, Inc.
Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
01/26
07/31
NCT05255666: Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Withdrawn
2
42
NA
Pembrolizumab, Keytruda, Liposomal Irinotecan, NaI-IRI
Washington University School of Medicine, Merck Sharp & Dohme LLC, Ipsen
Triple Negative Breast Cancer, Brain Metastases
01/27
01/30
NeoTAILOR, NCT05837455: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Recruiting
2
81
US
VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay, Anastrozole, Combination anthracycline and/or taxane based treatment
Washington University School of Medicine, Swim Across America, The Foundation for Barnes-Jewish Hospital
Breast Cancer, Cancer of the Breast
11/27
11/27
NCT04331067: Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Active, not recruiting
1/2
15
US
Paclitaxel, Taxol, Carboplatin, Paraplatin, Nivolumab, Opdivo, BMS-936558, Cabiralizumab, BMS-986227, Tumor biopsy, Bone marrow, Blood draw
Washington University School of Medicine, Bristol-Myers Squibb
Triple Negative Breast Cancer
03/23
05/26
REVERT, NCT05384119: Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Completed
1/2
6
US
TTI-101, Palbociclib, Ibrance ®, Aromatase inhibitor (AI), fulvestrant, ribociclib
Tvardi Therapeutics, Incorporated
Breast Cancer
04/24
04/24
NCT06374459: Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Not yet recruiting
1/2
152
US
Zumsemetinib, ATI-450, Capecitabine, Zoledronic acid, Denosumab
Washington University School of Medicine, United States Department of Defense, Aclaris Therapeutics, Inc.
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
06/32
06/32
NCT04606342: ATI-450 in Combination With Paclitaxel or Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer With Bone Metastasis

Not yet recruiting
1/2
150
US
ATI-450, Paclitaxel, Capecitabine, Antiresorptive Agents
Washington University School of Medicine, Aclaris Therapeutics, Inc., United States Department of Defense
Breast Cancer, Cancer of Breast
05/25
04/28
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
NCT03939897: Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Active, not recruiting
1
24
US
Abemaciclib, LY 2835219, LY-2835219, LY2835219, Verzenio, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Diagnostic Imaging, Medical Imaging, Echocardiography, EC, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ICI-182780, ICI182780, ZD 9238, ZD-9238, ZD9238, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Recurrent Breast Carcinoma
06/23
07/25
NCT05791474: ATI-2231 in Advanced Solid Tumor Malignancies

Withdrawn
1
36
NA
ATI-2231
Washington University School of Medicine, Aclaris Therapeutics, Inc.
Advanced Solid Tumor, Advanced Solid Tumor Malignancies
06/25
06/25
NCT00353483: Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

Recruiting
N/A
300
US
Peripheral blood draw, Breast tissue collection, Bone marrow biopsy
Washington University School of Medicine
Breast Neoplasms
08/25
08/25
NCT04968964: Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Recruiting
N/A
55
US
DiviTum® TKa assay, Study Care Plans
Washington University School of Medicine, Biovica
Breast Cancer, Cancer of the Breast
08/27
09/29
NCT04354064: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Recruiting
N/A
100
US
Washington University School of Medicine, Roche Sequencing Solutions, The Foundation for Barnes-Jewish Hospital, National Center for Advancing Translational Sciences (NCATS), Radiological Society of North America, Skandalaris, The V Foundation for Cancer Research, National Institute of General Medical Sciences (NIGMS)
Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
12/25
12/25
NCT05977036: BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

Recruiting
N/A
65
US
DiviTum® TKa assay, CDK4/6 + Endocrine therapy
Washington University School of Medicine, Biovica
Metastatic Breast Cancer, Unresectable Breast Cancer
09/34
09/34
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Krekow, Lea
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Mathews, Sandy
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Gold, Linsey
PREDICT, NCT03448926: The Registry:

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37

Download Options